Jiangsu Hengrui Pharmaceuticals(600276.SH): Rivilutamide Tablets Receives Drug Clinical Trial Approval Notice

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for Rivilutamide Tablets, and will soon initiate clinical trials for prostate cancer. Specifically: a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of Rivilutamide combined with androgen deprivation therapy (ADT) versus placebo combined with ADT in the treatment of high-risk localized or high-risk biochemical recurrence (BCR) prostate cancer after radical surgery/radiotherapy. Rivilutamide Tablets are a second-generation AR inhibitor that, compared with first-generation AR inhibitors, exhibits stronger AR inhibitory effects and has no agonistic activity. The company's Rivilutamide Tablets were approved for marketing in 2022 for the treatment of patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).